Medulloblastoma (the most common malignant childhood brain tumor) is separated into four molecular groups, with Group 3 bearing the worst prognosis. By studying EP300 and CBP, critical proteins in Group 3 medulloblastoma cells, scientists at St. Jude Children’s Research Hospital have designed a way to enhance anti-tumor activity by targeting a specific part of these proteins. This targeted approach significantly reduced cancer cell growth.
This article was originally published on MedicalXpress.com
